Homeland Defense News; Wave Dispersion Technologies, Inc. Achieves U.S. Department of Homeland Security SAFETY Act Designation

WhisprWave Floating Security Barriers Designated as a Qualified Anti-Terrorism Technology

SUMMIT, N.J. - April 14, 2011 - (Investorideas.com newswire, Homelanddefensestocks.com) Wave Dispersion Technologies, Inc. (WDT) the industry's premier provider of boat barriers and floating security barriers, has earned the prestigious United States Department of Homeland Security (DHS) SAFETY Act Designation, and the WhisprWave Small Craft Intrusion Barrier (SCIB) and the WhisprWave Vessel Exclusion Barrier (VEB) products are now designated as Qualified Anti-Terrorism Technologies (QATT).

The Support Anti-terrorism by Fostering Effective Technologies Act of 2002 (SAFETY Act) provides important legal liability protections for providers of QATT, and for customers who use them. The goal of the SAFETY Act is to encourage providers to develop and deploy new and innovative anti-terrorism products and services by providing risk mitigation and liability protections. Congress has stated that the purpose of the SAFETY Act is to "ensure that the threat of liability does not deter potential manufacturers or sellers of anti-terrorism technologies from developing and commercializing technologies that could save lives."
WhisprWave Boat barriers provide a strong deterrent against the threat of a small boat being used to deliver a Water Borne Improvised Explosive Device (WBIED) against another vessel, maritime critical infrastructure, or other key resources. This specific scenario was detailed as a real and significant threat in the Department of Homeland Security's Small Vessel Security Strategy published in 2008 and updated in 2010.
"We feel that WDT's WhisprWave boat barriers SAFETY Act designation will help us to better support DHS's overall mission, mitigate the small boat threat, provide growth opportunities for our small business and lead to job creation,” said Dennis G. Smith, Founder and CEO of WDT.
To qualify for the SAFETY Act Designation, WDT submitted a formal application to the DHS that underwent a technical and economic evaluation. Technologies eligible for SAFETY Act status include products, equipment, services, devices and information technologies. These must be intended to limit the harm that might result from acts of terrorism and to detect, identify, prevent or deter such acts.
"Very few companies have achieved this type of approval from DHS, and the level of scrutiny involved is extraordinary. This definitely represents a vote of confidence in the technology,” said Dana Rozycki of Rozycki Associates, LLC, a consulting firm that assisted with the application process.
For more information, visit http://www.whisprwave.com or call Jonathan B. Smith at (908) 233-7503.
About Wave Dispersion Technologies, Inc.:
Wave Dispersion Technologies, Inc. is the world's leading manufacturer and marketer of floating security barriers and floating wave attenuators, with over 50 product installations, on four continents, of its patented WhisprWave line of innovative maritime solutions for the following markets: government, military, commercial and consumer. The Company has been developing the technology for 15 years and holds eight Domestic and International Patents for design and utility, with another 20 patents pending. The Company has received U.S. Department of Homeland Security SAFETY Act Designation and the products have been designated as Qualified Anti-Terrorism Technologies (QATT).
About Rozycki Associates, LLC:
Rozycki Associates, LLC assists federal contractors with contracts management and regulatory compliance, with a focus on GSA Schedule negotiation and management.
Contact:
Jonathan B Smith
>Chief Operating Officer
Wave Dispersion Technologies, Inc.
908-233-7503
jonathan.smith@whisprwave.com
www.whisprwave.com
Wave Dispersion Technologies, Inc. (WDT) is a showcase private defense and security company on Investorideas.com defense content portals;
www.HomelandDefenseStocks.com and www.nationalhomelandsecurityknowledgebase.com

Biotech/ Biodefense Stock Trading Alert; Emergent Biosolutions (NYSE: EBS) Hits 52 Week High

Biodefense Stocks Sector Snapshot; (OTCBB: AEMD), (NASDAQ GM: DYSL), (NYSE Amex: PIP), (AMEX: PLX ), (NasdaqGM: SIGA)

Point Roberts, WA - April 14, 2011 - Investorideas.com, a leader in sector stock research including biotech and biodefense stocks issues a trading alert on Emergent Biosolutions, Inc. (NYSE: EBS) as it hit a 52 week high in Wednesday’s trading. The Company reported its chairman and chief executive officer, has been recognized as Biotech CEO of the Year during the Vaccine Industry Excellence (ViE) Awards at the World Vaccine Congress.

Biotech/ Biodefense Stocks Sector Snapshot ( as of close April 14 th)

• Aethlon Medical (OTCBB: AEMD) closed at $0.1036 on over 242,000 shares, with its 52 week range of $0.096 - 0.35
• Dynasil Corporation (NASDAQ GM: DYSL) ended at $4.14, with a 52 week range of $ 2.35 - 7.48
• Emergent Biosolutions, Inc. (NYSE: EBS ) closed at $24,68 hitting its 52 week high; $14.11 - 25.24
• PharmAthene, Inc. (NYSE Amex: PIP) finished trading at $3.17, its 52 week range of $1.25 - 4.96
• Protalix BioTherapeutics, Inc. (AMEX: PLX ) closed at $7.24, up 0.15 (2.12%)
• Siga Technologies (NasdaqGM: SIGA ) ended trading at $13.4, up 0.48 (3.71%) on over 437,000 shares

Recent News:
Emergent BioSolutions Chairman and CEO Fuad El-Hibri Named Biotech CEO of the Year at the World Vaccine Congress
ROCKVILLE, Md.--- Emergent BioSolutions Inc. (NYSE: EBS ) announced that Fuad El-Hibri, its chairman and chief executive officer, has been recognized as Biotech CEO of the Year during the Vaccine Industry Excellence (ViE) Awards at the World Vaccine Congress. The ViE awards showcase excellence and honor accomplishments of both individuals and companies in the global vaccine industry.
"This award is a testament to the collective efforts of the Emergent BioSolutions team, who on a daily basis and all over the world, lives out the corporate mission – to protect life,” said Mr. El-Hibri. "Our team shares a passion and commitment to make vital contributions to address unmet and underserved medical needs. It is an honor to be recognized for the work that we do.”
In selecting the winner for this category, the distinguished panel of judges evaluated the finalists based on their commitment to disease prevention and treatment, leadership, contribution to company performance, communication, and vision, industry influence, and achievements in company positioning and status.
Aethlon Medical (OTCBB: AEMD) Announces Multi-Target Exosome Assay Validation
SAN DIEGO - April 12, 2011 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB: AEMD) announced today that its wholly owned subsidiary Exosome Sciences, Inc. (ESI) has validated the ability of its Enzyme Linked Lectin Specific Assay (ELLSA) to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal. In July 2010, ESI disclosed that it filed a patent relating to the development of an assay that would allow researchers to detect exosomes in blood and other fluids. In addition to research opportunities, Aethlon Medical plans to test ELLSA as a diagnostic to quantify the therapeutic capabilities of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the circulatory system of those afflicted with cancer. ESI is now preparing a market survey that will be provided to researchers to determine market demand and pricing for ELLSA as a research tool.
Full news: http://www.investorideas.com/CO/AEMD/news/2011/04121.asp
Biodefense Company Snapshots; Aethlon Medical (OTCBB: AEMD),
Aethlon Medical (OTCBB: AEMD)
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
More: www.aethlonmedical.com
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
Visit the Aethlon Medical (OTCBB: AEMD) showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Emergent Biosolutions, Inc. (NYSE: EBS )
Emergent BioSolutions protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent's marketed and investigational products target infectious diseases, oncology and autoimmune disorders. www.emergentbiosolutions.com

About www.InvestorIdeas.com
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more Biodfense stocks at Investorideas.com
http://www.investorideas.com/bds/stock_list.asp
Research Biotech Stocks atInvestorideas.com
http://www.investorideas.com/BIS/Stock_List.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech,  biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011     
Aethlon Medical ( OTCBB:AEMD) :Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.  
800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com

A Broad-Spectrum Treatment Strategy to Address HIV, Hepatitis-C (HCV) and other Infectious Disease Conditions; Q&A with Aethlon Medical (OTCBB: AEMD) CEO, Jim Joyce

Point Roberts, WA. - April 14, 2011 � Investorideas.com, a leader in sector stock research presents a new interview in its series of biotech Q&A's, featuring Jim Joyce, CEO of Aethlon Medical (OTCBB: AEMD).

The Hemopurifier® from Aethlon Medical is a first-in-class medical device candidate to treat infectious disease. Human studies have documented that the Hemopurifier® can significantly reduce viral load in Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients in the absence of antiviral drugs. A study is currently underway to demonstrate the benefit of the Hemopurifier® as an adjunct to HCV drug therapy. Additional details can be accessed online at www.aethlonmedical.com
Q&A Interview
InvestorIdeas: How does your Hemopurifier® differ from drug therapies to treat infectious disease?
Mr. Joyce: Well, our approach is a complete departure from the consensus approach of introducing drug agents into the body to inhibit viral replication. As you are likely aware, these agents can have countering side effects or mechanisms of action that may not be fully understood. So, instead of adding agents into the body, our Hemopurifier® subtracts or removes viruses and other harmful particles from circulation without drug-related side effects. We think our therapeutic filtration approach could redefine the premise of how to treat infectious disease and we believe our strategy is far more innovative than another me-too drug inhibitor.
InvestorIdeas: Is a device that removes harmful particles from the body really considered to be innovative?
Mr. Joyce: The idea of a therapeutic filtration device that can remove harmful particles from circulation is not original. The basis of kidney dialysis, which keeps individuals with renal disease alive, is based on therapeutic filtration. However, like dialysis, previous therapeutic filtration strategies have sought to remove particles from circulation by molecule size, which is an indiscriminate approach that can also remove elements from circulation that are required for health. This factor has primarily limited the use of therapeutic filtration to niche markets. Our Hemopurifier® is truly innovative in the sense that we discriminate to selectively remove infectious viruses and other harmful particles from the entire circulatory system. It is this advancement that allows us to pursue opportunities in the much larger infectious disease and cancer markets.
InvestorIdeas: So it would seem your Hemopurifier® is positioned as a competitor to drug therapies.
Mr. Joyce: That is certainly not our intent. In fact, we expect to be an ally to the drug industry for several compelling reasons. First, if you really want to enhance or extend the benefit of drug therapies, you remove the strains of viruses that are causing drugs to fail and you do it without adding drug toxicity or interaction risks. But to fully unlock the capability of drug therapies you need to provide other complementary mechanisms that are beyond the reach of drugs. In that regard, we provide a strategy to address the toxins shed from viral surfaces to kill immune cells and particles known as exosomes that allow viruses to transport other disease-enhancing particles below the surveillance of the immune system. So our device in combination with drug therapy would seem to be a win-win scenario.
InvestorIdeas: What if a virus is not treatable with drug therapy?
Mr. Joyce: In reality, a vast majority of the viruses that are known to be infectious to man are not treatable with drugs. In scenarios that are life threatening, our Hemopurifer® is likely to be the sole strategy to address viral infections that are not treatable with drugs. For this reason, our Hemopurifier® is immensely valuable as new viruses like the coronavirus underlying the SARS outbreak of 2003 will emerge naturally in the future. We also face the looming threat of biological weapons purposely designed to defeat drug therapies. In either case, our Hemopurifier® provides a decision free first response that can augment the body's own immune response to such exposures, which is certainly more logical than an post-exposure strategy comprised of first identifying the virus that is killing people, and then establishing post-death research programs that may or may not yield a viable treatment candidate years after the fact.
InvestorIdeas: Thank you.
About Aethlon Medical ( OTCBB: AEMD )
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC (OTC BB: AEMD) Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock) Effective March 15, 2011       
800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com

AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011

Pharma News; BioSante Pharmaceuticals (NASDAQ: BPAX) Reports Teva New Drug Application (NDA) for Testosterone Gel, Bio-T-Gel™

New Drug Application (NDA) Accepted for filing by FDA

LINCOLNSHIRE, Ill. - April 13, 2011 (Investorideas.com newswire) - Pharma stock news; BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) reports a New Drug Application (NDA) has been accepted for filing by the U.S. Food and Drug Administration (FDA) following submission in January 2011 by a subsidiary of Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA). The FDA has assigned a PDUFA date of November 14, 2011. The PDUFA date is the target date for the FDA to complete its review of the NDA.

Bio-T-Gel is a testosterone gel for the treatment of male hypogonadism or low testosterone levels. Bio-T-Gel was developed initially by BioSante, and then it was licensed to Teva for late stage clinical development. Teva is responsible for all Bio-T-Gel regulatory and marketing activities. BioSante will receive certain milestone payments and royalties upon commercialization. The current U.S. market for male testosterone products is over $1.2 billion.
"We are extremely excited by Teva's NDA filing of Bio-T-Gel," said Stephen M. Simes, BioSante's president & CEO. "We are confident that Teva has the expertise and resources to capture significant market share once Bio-T-Gel is launched. We look forward to receiving milestone payments and royalties on Bio-T-Gel after approval and launch."
About Male Hypogonadism
Typically, a man's testosterone level is considered low if it's below a level of approximately 300 ng/dL. Low testosterone can be caused by a signaling problem that occurs between the brain and the testes that causes the production of testosterone to drop below normal. Low testosterone also can occur when the body can't make normal levels of testosterone and can lead to a medical condition known as hypogonadism that has many symptoms including fatigue, decreased energy, reduced sexual desire and depressed mood.
It is estimated that low testosterone affects more than 4 to 5 million men in the U.S. Common symptoms include reduced sex drive, decreased energy, loss of body hair or reduced shaving, and depressed mood. There is no cure for hypogonadism. It is a medical condition that usually requires ongoing treatment.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com

Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).

Gaming Stocks Sector Close-Up; Investors Betting on Gaming Stocks See Gains; (NYQ: LVS), (NYQ: MGM), (NMS: PENN), (NMS: WYNN)

POINT ROBERTS, WA - April 13, 2011 - InvestorIdeas.com is a leader in investor stock research by sector, releases a sector snapshot on gaming stocks for April 13, 2011.

The Wall Street Journal reported M G M MIRAGE (NYQ: MGM) * “ said it reached an agreement with Macau mogul Pansy Ho that will give the U.S. casino operator a majority stake in its Chinese joint venture after the venture's planned initial public offering. A date hasn't yet been set for the offering but is expected in May. The IPO could raise around US$1 billion, a person familiar with the situation said earlier this month.” MGM (NYQ: MGM) was up over 6.8% in morning trading.
Gaming Stocks Sector Snapshot

• International Game Technology (NYSE: IGT ) trading at $15.8, up 0.49 (3.19%) 10:55AM EDT
• Isle of Capri Casinos, Inc. (NMS: ISLE) trading at $9.06, up 0.06 (0.67%) 10:44AM EDT
• LAS VEGAS SANDS CORP (NYQ: LVS) trading at 44.83 1.37 (3.15%) 11:02AM EDT
• M G M MIRAGE (NYQ: MGM) trading at $13.47, up 0.86 (6.82%) 10:50AM EDT
• Penn National Gaming, Inc (NMS: PENN) trading at $37.09, up 0.35 (0.95%) 11:00AM EDT
• Shuffle Master, Inc.(NasdaqGS: SHFL ) trading at $10.70, up 0.01 (0.09%) 10:52AM EDT
• Wynn Resorts, Limited (NMS: WYNN) trading at $135.32, up 5.18 (3.98%) 10:49AM EDT

For a directory of gaming stocks visit:
http://www.gamingindustrystocks.com/GIS/Stock_List.asp
Market Snapshot

• Dow 12,304.56 +40.98 +0.33%
• Nasdaq 2,768.35 +23.56 +0.86%
• S&P 500 1,318.28 +4.12 +0.31%
• 10 Yr Bond(%) 3.52% +0.02
• Oil 107.16 +0.91 +0.86%
• Gold 1,457.80 +4.90 +0.34%

* http://online.wsj.com/article/SB10001424052748703730104576260582978118002.html?mod=yahoo_hs
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Sign up for free stock alerts and sector alerts at Investorideas.com

About our Gaming Portal:
www.GamingIndustryStocks.com, a portal within the InvestorIdeas.com® content umbrella, does not make recommendations, but features industry and stock news, exclusive articles and financial columnists, audio interviews and Podcasts, investor conferences, Blogs, and a directory of stocks in the sector.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
For Additional Information:
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com, GamingIndustryStocks.com

Biotech/Pharma Stock News; BioSante Pharmaceuticals (NASDAQ: BPAX) Announces Teva New Drug Application for Bio-T-Gel™

LINCOLNSHIRE, Ill. - April 13, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that a New Drug Application (NDA) has been accepted for filing by the U.S. Food and Drug Administration (FDA) following submission in January 2011 by a subsidiary of Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA). The FDA has assigned a PDUFA date of November 14, 2011. The PDUFA date is the target date for the FDA to complete its review of the NDA.

Bio-T-Gel is a testosterone gel for the treatment of male hypogonadism or low testosterone levels. Bio-T-Gel was developed initially by BioSante, and then it was licensed to Teva for late stage clinical development. Teva is responsible for all Bio-T-Gel regulatory and marketing activities. BioSante will receive certain milestone payments and royalties upon commercialization. The current U.S. market for male testosterone products is over $1.2 billion.
"We are extremely excited by Teva's NDA filing of Bio-T-Gel," said Stephen M. Simes, BioSante's president & CEO. "We are confident that Teva has the expertise and resources to capture significant market share once Bio-T-Gel is launched. We look forward to receiving milestone payments and royalties on Bio-T-Gel after approval and launch."
About Male Hypogonadism
Typically, a man's testosterone level is considered low if it's below a level of approximately 300 ng/dL. Low testosterone can be caused by a signaling problem that occurs between the brain and the testes that causes the production of testosterone to drop below normal. Low testosterone also can occur when the body can't make normal levels of testosterone and can lead to a medical condition known as hypogonadism that has many symptoms including fatigue, decreased energy, reduced sexual desire and depressed mood.
It is estimated that low testosterone affects more than 4 to 5 million men in the U.S. Common symptoms include reduced sex drive, decreased energy, loss of body hair or reduced shaving, and depressed mood. There is no cure for hypogonadism. It is a medical condition that usually requires ongoing treatment.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com

Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).

Oil and Gas Trading Alert; American Petro-Hunter (OTCBB: AAPH) NOS227 Oil Well Completion on Track Amidst Resurgence of "Big Oil" in Oklahoma

SCOTTSDALE, AZ - April 13, 2011 (Investorideas.com Energy Newswire) - American Petro-Hunter, Inc. (OTC.BB:AAPH) ("American Petro-Hunter" or the "Company") is pleased to announce that while the recent rise in oil prices to over $112 a barrel has spawned an upsurge in activity likened to the "Return of Big Oil to Oklahoma," the operators of the NOS227 well report their excellent relations with contract well service providers have ensured scheduled well completion operations are on track at the North Oklahoma Project.

The "multi-stage surge frack," designed by the engineering team is to be implemented by Basic Well Services of Cushing Oklahoma. This rig service company has extensive expertise in successfully completing both vertical and horizontal wells in the Mississippi formation in both Oklahoma and Kansas.
Management believes the frack will result in the well producing oil at an Initial Production Rate ("IPR") of 300 barrels of oil per day (BOPD). Once the production rate has been established over several weeks, the Company plans to commence drilling an additional vertical offset well and enjoys the latitude to drill up to an additional 15 wells on the Yale Prospect lease component of its North Oklahoma Project.
American Petro-Hunter is simultaneously finalizing plans for its first horizontal well on the nearby "Ripley Prospect." The acreage is located in 100 foot thick sections of Mississippi in an area experiencing aggressive exploitation by major operators investing heavily in laterally drilled, horizontal wells.
The Mississippi has produced 317 million barrels to date, and given the known data is a low reservoir risk opportunity. With under $2.5 million in drilling costs per well, many rigs are already mobilized with more on the way. Examples of regional wells such as the Eagle Energy LLC Avard 1H-31 which made 922 barrels in the first 24 hours and gas at 4.5 MMCF as well as Range Resources two Mississippian horizontals tested in a 24 hour period at a combined 1,314 BOE per day have energized the play.
In the media, Oil and Gas Investor Magazine recently reported in its April edition that in February there were 19 rigs drilling horizontal wells in the play with reports that companies such as Sandridge Energy plan to drill 138 horizontal wells this year at a cost of $248 million.
As previously reported by the Company, the Calyx C&N 25-1H well a mile and a quarter from the Ripley lease has been speculated to have had initial production rates (I.P.) of 1,000 barrels per day (BPOD). It is common knowledge that these horizontal wells can generate higher reserves than vertical wells which historically produce in the 30,000 to 50,000 barrels per location range. Data shows that horizontal wells offer four to five times the production in the 150,000 barrel per well range.
Company President and C.E.O. Robert McIntosh states, "The regional Mississippi Play has become extremely busy with the recent news of large wells being brought online and the sheer number of wells being drilled and completed. We have been prudent in securing our drilling contractors and well service companies in advance and will meet our scheduled timetable for the 2011 drilling program, despite the upsurge in the midst of the recent oil boom."
Mr. McIntosh continues, "We are working with our partners to finalize the plans, permitting and A.F.E.s on our 2,000 acre Ripley Prospect. A location for the first Mississippi horizontal has been engineered and proposed. We have been advised that a 1,500 to 1,800 foot lateral well along the Mississippi will exploit a 320 acre parcel near to the Calyx operations and we hope to announce a spud date shortly."
About American Petro-Hunter, Inc. (OTCBB: AAPH)
The Company is a goal-oriented exploration and production (E&P) Company aiming to become an intermediate level oil and gas producer within 12 months. The Company is in production at the Poston Project in Trego County Kansas with new drilling activity and production underway at the North Oklahoma Oil Project. With the achievable target of becoming a 1000 BOE producer as our goal, American Petro-Hunter is actively on the "hunt" for domestic petroleum assets. Visit us at: www.americanpetrohunter.com
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of our exploration program at our properties and any anticipated future production. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with petroleum exploration and development stage exploration companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-KSB for the most recent fiscal year, our quarterly reports on Form 10-QSB and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
American Petro-Hunter, Inc.
Robert McIntosh
President & C.E.O.
To find out more about American Petro-Hunter, Inc. (OTC.BB:AAPH), visit our website at www.americanpetrohunter.com
Contact:
Investor Relations:
Mountainview IR Services, Inc.
1-888-521-7762
investors@americanpetrohunterinc.com

Visit the AAPH showcase profile at Investorideas.com
Request News and Info on AAPH
Disclosure, Disclaimer/ AAPH is a paid advertising client on Investorideas.com.
American Petro-hunter Inc. (AAPH.OB) Oct 2010 - one month showcase energy stock on Investorideas.com and energy portals and blogs (three thousand per month)

Security Stocks; Visualant (OTCBB:VSUL) Subsidiary TransTech Systems Announces Access Card Programmer Incorporated in ID Card Printers

SEATTLE - April 12, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color based identification and diagnostic solutions, an emerging leader in security and authentication systems technology and distributor of a wide variety of security solutions through its wholly-owned subsidiary, TransTech Systems, Inc., is pleased to announce that TransTech Systems has successfully incorporated an industry standard access card programmer into an identification card printer for production of personalized access control credentials.

Traditionally, access cards are pre-programmed by providers and shipped to the users for future use. At the time of card issuance, there is a two step process whereby the card is read by an access reader to get the pre-programmed number associated with the card and then the card is printed with the card holder's information. With TransTech's integration of Farpointe Data's Cards on the Go™ COG1000 directly into the printer, the process can be accomplished in one step. Further, the requirements for ordering pre-programmed stock and the related worries about the security of this stock before issuance are eliminated.
Cards on the Go™ COG-1000 is an access control credential programmer designed to give security access control professionals and system integrators the ability to program both proximity and contactless smartcard credentials. The Cards on the Go™ COG-1000 desktop solution includes a USB-based desktop programmer, a USB cable, programming software and 100 preloaded programming tokens. The Cards on the Go™ card printer based solution configuration will vary by printer manufacturer. OEM solutions for larger systems integrators may be available.
Adding Cards on the Go™ technology to identification card printer solutions provides a unique product offering for TransTech's security reseller channel. TransTech Systems is currently the only provider of this technology. The unit was debuted at the ISC West Security Industry trade show in Las Vegas last week. Full production is planned within sixty days.
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
About Farpointe Data
Since 2003 Farpointe Data (www.farpointedata.com), a privately held company located in California�s Silicon Valley, has offered radio frequency identification (RFID) readers, cards and tags for access control. These advanced products span the frequency spectrum, each including a host of unique Farpointe-only features. These products include the 125-kHz Pyramid Series Proximity� line of proximity readers, cards and tags, the Delta™ line of multi-technology (combining 13.56-MHz & 125-kHz operation) contactless smartcard readers, cards and tags, as well as the 433-MHz Ranger™ line of long-range transmitters and receivers.
Farpointe's exacting RFID designs, superior manufacturing, competitive pricing and excellent performance have earned the trust of its partners, access control system manufacturers, and achieved recognition as the industry's leading independent manufacturer of readers, cards and tags.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com

Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs. (2500 per month)

Biotech/Biodefense Stock News; Aethlon Medical (OTCBB: AEMD) Announces Multi-Target Exosome Assay Validation

SAN DIEGO - April 12, 2011 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB: AEMD) announced today that its wholly owned subsidiary Exosome Sciences, Inc. (ESI) has validated the ability of its Enzyme Linked Lectin Specific Assay (ELLSA) to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal. In July 2010, ESI disclosed that it filed a patent relating to the development of an assay that would allow researchers to detect exosomes in blood and other fluids. In addition to research opportunities, Aethlon Medical plans to test ELLSA as a diagnostic to quantify the therapeutic capabilities of the Aethlon Hemopurifier� to remove immunosuppressive exosomes from the circulatory system of those afflicted with cancer. ESI is now preparing a market survey that will be provided to researchers to determine market demand and pricing for ELLSA as a research tool.

"We are grateful to those organizations that collaborated in beta-testing the capabilities of ELLSA to detect exosomes, which are increasingly being recognized as particles that deplete immune cells or provide a mechanism to transport disease-enhancing factors below the surveillance of the immune system,� stated Aethlon CEO, Jim Joyce. "Additionally, the ESI ELLSA provides the potential for a near-term revenue stream that complements the therapeutic programs we are actively advancing at Aethlon Medical"
About Aethlon Medical
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:

1. Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
2. Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
3. Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
4. Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.

The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com

AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011

Gold Stocks; Gold Bullion (TSX-V: GBB) Develops Plans to Spin Off Its Castle Silver Mine

Vancouver, British Columbia - April 12, 2011 (Investorideas.com Mining stocks Newswire) - Gold Bullion Development Corp. (CDNX:GBB.V) (Other OTC:GBBFF.PK) (the "Company" or "Gold Bullion") announces its intention to spin off its silver mine, the Castle (Milner) Property in the Gowganda mining district of Ontario, to Gold Bullion shareholders. The Company expects that the proposed spin-off will be in the form of shares of a newly-incorporated, public company called "Castle Silver Mines Inc."

The Company holds a 100% interest in the Castle (Milner) Property encompassing 34 claims and 2 parcels located in the Haultain and Nicol Townships of Ontario, subject to the royalties stated below.
Gold Bullion has engaged GENIVAR to prepare a technical report in accordance with National Instrument 43-101. There is no current resource estimate for the Castle (Milner) Property.
The 1989 Cobalt Residents Geologist's Office reported that the Castle Mine, in operation since 1917, produced 763,127 kilograms (22.26 million ounces) of silver to 1989, from the No. 3 shaft alone. Included in this total is the most recent production from the Castle Mine during the 1979 to 1989 term by Agnico-Eagle Mines Limited which was reported as follows: 101,024 tonnes milled, 91,421 kilograms (2.67 million ounces) silver, 34,597 kilograms cobalt and 10,180 kilograms copper. Operations ceased in 1989 due to low silver prices. There are two other shafts in existence on the property, but the records are not complete enough to declare their full historical production numbers.
The Company has initiated a small orientation IP geophysical grid across the Castle (Milner) Property. In addition, a drill program begun mid-February, 2011, is also now in progress. A total of 6,000m drilling is planned. This is intended to test for continuation of known structures, as well as test horizons within and adjacent to the Nipissing diabase in the Gowganda area, which are still unexplored.
Historically, exploration in the Gowganda - Elk Lake area of the Nipissing diabase has focused on the upper 1/3 of the sill. Most of the resulting production has been mined from this horizon. However, looking at the entire Nipissing diabase, an estimated 75% or more of the silver - in silver mines between Gowganda and Silver Centre in South Lorrain, Cobalt, Ontario (about 160 km to the south) - has been mined from outside this horizon.
Compilation of all existing and available information on the property is underway and will be digitized in 2011 to allow a more thorough analysis of the geology and known mineralization. A great deal of information and historic underground geological information has recently been acquired and is currently being added to the existing database.
Frank Basa, President and CEO, said, 'Our strategy is to find past producing mines in mining-friendly jurisdictions, look to increase the resource and then put them back into production. We adopt this strategy because, with infrastructure and historical drilling already in place, this a comparatively quick and economic way to move forward. Some of the historical production at the Castle Silver Mine has been very exciting with grades up to 26 ounces per tonne.
With all the success we've been having over at our Granada project, the Castle Silver project has, in my view, been rather overlooked. We felt the best way to realize its value for our shareholders is to spin it off into a separate company. At around $36 an ounce, silver prices look very strong and there is so much future potential for it both as an industrial and a monetary metal. Yet quality companies that are entirely focused on silver seem in such short supply. So, going forward, we are very excited about Castle Silver Mines Inc.
In addition, we're very excited about the cobalt.'
Gold Bullion is in the process of analyzing the most efficient and expeditious transaction structure for the spin-off. The details of the proposed transaction, the number of shares of Castle Silver Mines Inc. to be distributed to Gold Bullion shareholders, and the record date for the proposed share distribution have yet to be determined. The proposed transaction is subject to the Company obtaining all necessary board and regulatory approvals. Gold Bullion expects that the proposed transaction will be completed before the third quarter of 2011.
The royalties payable on the Castle Silver Mine are as follows;
i) a sliding scale royalty on silver production which will start from 3% when the price of silver is US$15 or lower per troy ounce and up to 5% when the price of silver is greater than US$30 per troy ounce;
ii) a 5% gross overriding royalty on the sale of products derived from the property with a minimum annual payment of $15,000 in the form of royalties on all future production from the property.
Gold Bullion's Qualified Person has not done sufficient work to classify the historical estimates referred to above as current mineral resources or mineral reserves, and the Company is not treating the said historical estimate as current mineral resources or mineral reserves. Accordingly, the historical estimates should not be relied upon. Mineral resources that are not mineral reserves do not have demonstrated economic viability.
This news release was written by Frank J Basa P.Eng., President and Chief Executive Officer of Gold Bullion Development Corp. in his capacity as a qualified person under NI 43-101.
About Gold Bullion Development Corp.
Gold Bullion Development Corp. is a TSX Venture listed junior natural resource company focusing on the exploration and development of its Granada Gold Property near Rouyn-Noranda, Quebec, and its high grade Castle Silver Mine in Gowganda, Ontario.
For more information on Gold Bullion Development Corp. (TSX-V: GBB, OTC PK: GBBFF), visit our web site: http://www.GoldBullionDevelopmentCorp.com
Frank J. Basa, P.Eng.
President and Chief Executive Officer
For further information contact:
Frank J. Basa, P.Eng., President and CEO: 1-416-625-2342
Roger Thomas, Director: 1-613-292-2438
Progressive Investor Relations (Canada) Tel (604) 689-2881 or email info@progressive-ir.com
Torrey Hills Capital (United States) Tel (858) 456-7300
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

Visit the GBB showcase profile at Investorideas.com
Request News and Info on GBB
Disclosure, Disclaimer/ GBB is a paid advertising client on Investorideas.com and our mining portals.

Wind Stocks Sector Snapshot; America's Wind Power Industry Grew by 15% in 2010

Point Roberts, WA - April 11, 2011 - Investorideas.com, a leader in cleantech stock research reports on recent wind stocks news and developments. The AWEA U.S. Wind Industry reported America's wind power industry grew by 15% in 2010 and provided 26% of all new electric generating capacity in the United States. Both the First Trust Global Wind Energy (FAN) and PowerShares Global Wind Energy (NasdaqGM: PWND) wind indices are up in morning trading.

Wind Stocks Snapshot

• Clean Wind Energy Tower, Inc. (OTCBB: CWET) trading at $0.29
• First Trust Global Wind Energy (FAN) trading at 11.95, up 0.16 (1.36%)
• PowerShares Global Wind Energy (NasdaqGM: PWND ) trading at 11.39, up 0.09 (0.83%)

Market Snapshot

• Dow 12,388.45 +8.40 +0.07%
• Nasdaq 2,769.82 -10.60 -0.38%
• S&P 500 1,326.01 -2.16 -0.16%
• 10 Yr Bond(%) 3.5850% +0.0150
• Oil 110.84 -1.95 -1.73%
• Gold 1,467.40 -6.00 -0.41%

Research more wind stocks with the renewable energy stocks directory:
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
Clean Wind Energy Tower, Inc. (OTCBB: CWET)
Clean Wind Energy, Inc., a wholly owned subsidiary of Clean Wind Energy Tower, Inc., was established to commercialize a number of proven and validated technologies and construction systems into a single large downdraft tower structure that use benevolent, non-toxic natural elements to generate electricity and clean water economically by integrating and synthesizing numerous proven as well as emerging technologies. In addition to constructing Downdraft Towers in the United States and abroad, Clean Wind Energy, Inc. has assembled a world class team of experienced business professionals, engineers and scientists with access to the breakthrough energy research upon which this technology is founded and the proven ability to bring the idea to market.
Clean Wind has filed several patents that the Company believes will further enhance this potentially revolutionary technology. The Company intends to establish partnerships at home and abroad to propagate these systems and meet increasing global demand for clean water and electricity .
www.cleanwindenergytower.com
Visit the showcase page at Investorideas.com : http://www.investorideas.com/CO/CWE/
Wind News:
U.S. wind industry continues growth, despite slow economy and unpredictable policies
AWEA U.S. Wind Industry Annual Market Report for 2010 underscores wind's affordability as domestic generation source
New York , N.Y. - April 11, 2011 (Investorideas.com renewable energy /green newswire) America's wind power industry grew by 15% in 2010 and provided 26% of all new electric generating capacity in the United States. With the 5,116 MW added last year, U.S. wind installations now stand at 40,181 MW, enough to supply electricity for over 10 million American homes.
"The American wind industry is delivering, despite competing with energy sectors that have permanent government subsidies in place," said Denise Bode, CEO of the American Wind Energy Association (AWEA). "Wind is consistently performing," she said, "adding 35% of all new generating capacity since 2007— that's twice what coal and nuclear added combined."
Full News : http://www.investorideas.com/news/2011/renewable-energy/04111.asp
About Investorideas.com and our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Sign up at Investor Ideas for free investor alerts including news on (OTCBB: CWET)
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET) advertising program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one thousand five hundred per month, 100,000 144 shares ) to be showcased as a renewable energy stock within its hub of sites and blogs.Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com.
Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
For more information about Investorideas.com contact:
800.665.0411, Email: dvanzant@investorideas.com or cvanzant@investorideas.com

Mining Stocks; LOMIKO (TSX-V:LMR; OTC:LMRMF) Sees New Investment in Cassiar by Chinese Firm as Positive Sign for the Vines Lake Gold Project

Vancouver - April 11, 2011 (Investorideas.com mining stocks newswire) � LOMIKO METALS INC. (TSX-V:LMR, OTC:LMRMF, Europe: ISIN:CA54163Q1028, WKN:A0Q9W7,) ("Lomiko" or "the Company) Lomiko Metals Inc. holds the rights to three contiguous mineral tenures, totaling 1,169 Ha (2,888 Acres) located in the southwestern corner of the Cassiar Gold District or 'Cassiar Gold Camp'.

Recent developments in the area include the completion of a major investment from Chinese Firm SkyOcean Venture Investments Ltd. in Hawthorne Gold Corp. Skyocean, together with joint actor China Mineral Holdings, holds a total of 83,954,499 shares representing a total of 44.22 per cent of the outstanding shares of Hawthorne on an undiluted basis.
CASSIAR AREA HIGHLIGHTS:

• Lomiko recently raised $ 400,000 for work on the Vines Lake Gold Project.
• Two significant anomalies have been identified by geophysical surveys On Lomiko's 100% owned Vines Lake Project.
• The claims cover formations of the Sylvester group, which are known to contain productive zones of gold mineralization in the area.
• The Vines Lake Property is located approximately two kilometres southwest of the former Erickson gold mine.
• Excellent infrastructure exists in the area. Highway 37 N bisects the property north to south. A fully permitted 270 tonne per day, gravity and flotation mill, power plant, assay laboratory and tailings impoundment facility is owned by Hawthorne.

Further, Lomiko announces a private placement to raise up to $400,000 from eligible participants through the sale of up to 5,000,000 units of a common share at a price of $0.08 per unit.
The units will consist of one common share and a warrant exercisable for up to 2 years at $0.12 to purchase one half of a common share. The funds will be allocated to cover any additional costs for the Company's exploration program and the remaining amount will be for general working capital.
The Company has agreed to pay a cash finder's fee of 10% in relation to the financing. Any shares issued will be subject to a four month hold period.
The above financing is subject to Regulatory approval.
For more information, please contact Paul Gill at 604-729-5312, email: info@lomiko.com or refer to the website at: www.lomiko.com
On behalf of Lomiko Metals Inc,
Signed: "A. Paul Gill"
A. Paul Gill, President & CEO
We seek safe harbor. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer/ Disclosure: The following news is paid for and /or published as information only for our readers. Lomiko Metals Inc. (TSX-V: LMR) three month showcase gold stock on Investorideas.com and all related mining portals and blogs (one thousand per month)
Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal .This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp